



The Future of Oncology - NESA's VIEZION's Project

Michael Stark

The New European Surgical Academy (NESA), Germany

Abstract

Despite impressive progress in various medical fields, the suggested post-operative Oncological Chemotherapy is still based on statistical results.

The FDA approved dozens of therapeutic monoclonal antibodies for metastatic colorectal cancer, which means that none is the optimal one.

Some improvement has been shown when the potential of genetic profiling of tumors enabled targeted chemotherapy.

In order to further improve the outcome, the New European Surgical Academy (NESA) initiated the VIEZION project for optimal post-operative oncological treatment which involves next to targeted chemotherapy the Pre Implantation Factor (PIF), stem cell therapy and immunology.

PIF, with its 15-amino acid structure, is unique for all mammals and prevents rejection of the conceptus by its host. It was found to be useful in many fields such as prevention of brain injury due to ischemia, protecting against irradiation and functions like a steroid without being one, avoiding its side effects. We believe that the PIF will have a major future role in oncological treatment.

Recently the role of Intalipid is being studied, and it has been shown that anesthetic medication based on fatty acids might prevent spread of cancer cells during surgery.

To improve the post-operative oncological outcome the NESA created an international oncological advisory board with members from different countries, comprising basic science members, geneticists, stem-cell scientists, and oncologists. Physicians and patients from different countries are already approaching the board and occasionally original and non-conventional modes of treatments are being suggested.

Biography

Prof. Dr. Michael Stark is specialized in Obstetrics and Gynecology with main interest. He is the scientific and medical advisor of the French 123 ELSAN Hospital Group. Since 2004 he has been the President of the New European Surgical Academy (NESA), an international inter-disciplinary surgical organization with members in 57 countries and in the last four years guest scientist at the Charite university hospital, Berlin. In 2011, Prof. Stark was nominated as the Medico Del Anno (Doctor of the Year) in Italy, and he is an honorary Member of the French, Polish, Russian and Italian Gynecological Associations. In the years 1983-2000 he was the medical director and head of Ob/Gyn department of the Misgav Ladach Hospital in Jerusalem, and between 2001 and 2009 the chairman of all Ob/Gyn departments of the HELIOS Hospital Group in Europe. He modified operations like the vaginal and abdominal hysterectomy and Cesarean Section and developed the concept of single-entry natural orifice surgery. And is involved in the development of the trans-oral thyroidec-tomy and the TransDouglas abdominal surgery.

[3rd International Webinar on Surgery and Anesthesia, July 22-22, 2020](#)

Citation: Michael Stark, The Future of Oncology - NESA's VIEZION's Project-, Surgery and Anesthesia, 3rd International Webinar on Surgery and Anesthesia, July 22-22, 2020, page 4